<DOC>
	<DOCNO>NCT01353664</DOCNO>
	<brief_summary>This study intend provide access Romidepsin participant receive Romidepsin trial sponsor Gloucester Pharmaceuticals Celgene Corporation participant investigator feel may benefit continue treatment Romidepsin .</brief_summary>
	<brief_title>A Rollover Study Patients Who Participated Other Romidepsin Protocols</brief_title>
	<detailed_description>Participants must previously participate Romidepsin study sponsor Gloucester Pharmaceuticals Celgene Corporation .</detailed_description>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Inclusion Criteria 1 . Previously participate fulfilled inclusion exclusion criterion one romidepsin clinical trial : ROMIADVM001 ( NCT01324310 ) , ROMIADVM002 ( NCT01324323 ) . Additional study add discretion medical monitor study 2 . Physician believe continued romidepsin treatment benefit participant . 3 . Understand voluntarily sign informed consent document prior study related assessments/procedures conduct . 4 . Able adhere study visit schedule protocol requirement . 5 . Negative urine serum pregnancy test females child bear potential ; 6 . All female child bear potential must use effective method contraception ( intrauterine contraceptive device [ IUCD ] double contraceptive method use condom diaphragm plus spermicide ) treatment period least 1 month thereafter . Male participant use contraception treatment period least 3 month thereafter . Female participant avoid use estrogencontaining contraceptive , since romidepsin may reduce effectiveness estrogencontaining contraceptive . An vitro binding assay determine romidepsin competes Î²estradiol bind estrogen receptor . Exclusion Criteria 1 . Concomitant use drug may cause significant prolongation correct measurement time start cardiac Q wave end T wave ( QTc ) . 2 . Concomitant use Cytochrome P 450 3A4 ( CYP3A4 ) strong inhibitor within 1 week trial medication . 3 . Concomitant use therapeutic warfarin due potential drug interaction . Use low dose warfarin another anticoagulant maintain patency venous access port cannula permit . 4 . Prior chemotherapy radiotherapy investigational agent last dose romidepsin precede romidepsin study . 5 . Participants pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>rollover protocol</keyword>
	<keyword>romidepsin</keyword>
	<keyword>Gloucester Pharmaceuticals</keyword>
	<keyword>Celgene Corporation</keyword>
	<keyword>continue treatment</keyword>
</DOC>